Erratum: Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

  • K. Reich (Contributor)
  • Jean Paul Ortonne (Contributor)
  • Urs Kerkmann (Contributor)
  • Yanxin Wang (Contributor)
  • Jean Hilaire Saurat (Contributor)
  • Kim Papp (Contributor)
  • R. G. Langley (Contributor)
  • Christopher Griffiths (Contributor)



<i>Background:</i> The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails. <i>Objective:</i> To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment. <i>Methods:</i> A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted. <i>Results:</i> Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI). <i>Conclusions:</i> Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores.
Date made available25 Jul 2017

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute
  • Manchester Institute for Collaborative Research on Ageing

Cite this